| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [J. W-R., S. X., J. L., R. B. A.]; and Division of Hematology and Medical Oncology, Royal Victoria Hospital, McGill University, Montreal, Quebec H3A 1A1, Canada [P. L.]
Chronic myelogenous leukemia is a neoplasm of pluripotent hematopoietic cells. The P210 Bcr-Abl oncoprotein is a deregulated cytoplasmic tyrosine kinase that has been shown to cause chronic myelogenous leukemia-like neoplasms in mice. Cytokines such as interleukin 3 and granulocyte/macrophage-colony-stimulating factor regulate the growth and differentiation of hematopoietic precursors. These cytokines activate two distinct signals to the nucleus. One signal is through the Ras pathway, and the second involves activation of Jak2. We demonstrated that Bcr-Abl co-immunoprecipitates with, and constitutively phosphorylates, the common ßc subunit of the interleukin 3 and granulocyte/macrophage-colony-stimulating factor receptors. Our data show that formation of this complex leads to the constitutive tyrosine phosphorylation of Jak2. It has been demonstrated that Bcr-Abl interacts with Grb2 and Shc, which in turn activates the Ras pathway. Our new findings raise the possibility that Bcr-Abl activates signaling through both pathways in a factor-independent fashion.
1 This work was supported by Grants CA65611 and CA16672 from the NIH. R. B. A. is the recipient of the Hubert L. Stringer Chair in Cancer Research. J. W-R., a postdoctoral fellow, was supported by Grant CA09299. Initial findings were presented in November of 1995 at the XVIII International Symposium on Leukemia and Related Diseases in Kyoto, Japan.
2 Present address: The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75235-9148.
3 To whom requests for reprints should be addressed, at Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
Received 5/ 7/96. Accepted 6/12/96.
This article has been cited by other articles:
|
|
 |
|
  S. Wong, J. McLaughlin, D. Cheng, K. Shannon, L. Robb, and O. N. Witte IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease PNAS, September 30, 2003; 100(20): 11630 - 11635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Laurent, D. L. Mitchell, Z. Estrov, M. Lowery, S. L. Tucker, M. Talpaz, and R. Kurzrock Impact of p210Bcr-Abl on Ultraviolet C Wavelength-induced DNA Damage and Repair Clin. Cancer Res., September 1, 2003; 9(10): 3722 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kurzrock, H. M. Kantarjian, B. J. Druker, and M. Talpaz Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics Ann Intern Med, May 20, 2003; 138(10): 819 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Ling, G. Ma, T. Sun, J. Liu, and R. B. Arlinghaus Bcr and Abl Interaction: Oncogenic Activation of c-Abl by Sequestering Bcr Cancer Res., January 15, 2003; 63(2): 298 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Donato, J. Y. Wu, J. Stapley, G. Gallick, H. Lin, R. Arlinghaus, and M. Talpaz BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood, January 15, 2003; 101(2): 690 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mukhopadhyay, S. Shishodia, J. Suttles, K. Brittingham, B. Lamothe, R. Nimmanapalli, K. N. Bhalla, and B. B. Aggarwal Ectopic Expression of Protein-tyrosine Kinase Bcr-Abl Suppresses Tumor Necrosis Factor (TNF)-induced NF-kappa B Activation and Ikappa Balpha Phosphorylation. RELATIONSHIP WITH DOWN-REGULATION OF TNF RECEPTORS J. Biol. Chem., August 16, 2002; 277(34): 30622 - 30628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Donato, J. Y. Wu, L. Zhang, H. Kantarjian, and M. Talpaz Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor {beta}-chain in BCR-ABL+ human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition Blood, May 1, 2001; 97(9): 2846 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis Cancer Res., March 1, 2001; 61(6): 2343 - 2355. [Full Text]
|
|
|
|
|
|
M. W. N. Deininger, J. M. Goldman, and J. V. Melo The molecular biology of chronic myeloid leukemia Blood, November 15, 2000; 96(10): 3343 - 3356. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Di Bacco, K. Keeshan, S. L. McKenna, and T. G. Cotter Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis Oncologist, October 1, 2000; 5(5): 405 - 415. [Abstract] [Full Text]
|
|
|
|
|
|
V. Lacronique, A. Boureux, R. Monni, S. Dumon, M. Mauchauffe, P. Mayeux, F. Gouilleux, R. Berger, S. Gisselbrecht, J. Ghysdael, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells Blood, March 15, 2000; 95(6): 2076 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiang, A. Lopez, T. Holyoake, A. Eaves, and C. Eaves Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia PNAS, October 26, 1999; 96(22): 12804 - 12809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Warmuth, M. Bergmann, A. Priess, K. Hauslmann, B. Emmerich, and M. Hallek The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr J. Biol. Chem., December 26, 1997; 272(52): 33260 - 33270. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
